A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Trial Profile

A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Nivolumab (Primary) ; Oregovomab (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ORION-01
  • Most Recent Events

    • 26 Jul 2017 According to an OncoQuest media release, to date, 6 patients have been enrolled in this trial.
    • 09 May 2017 According to a Quest PharmaTech media release, Dr. Tira Tan is the principal investigator of this trial.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top